Clinical trialNCT02348359TerminatedPhase 2Interventional

X-82 to Treat Age-related Macular Degeneration

SponsorTyrogenexEnrollment157AMDAge-Related Macular Degeneration (AMD)Exudative Age-related Macular DegenerationEye DiseasesMacular DegenerationMacular Degeneration, Age-related, 10+2 more conditions

View the registry record on ClinicalTrials.gov

Summary

The lay summary the sponsor registered on ClinicalTrials.gov.

The purpose of this study is to evaluate the safety and efficacy of X-82 in the treatment of vision loss due to wet AMD.

clinicaltrials.gov ↗

Investigators

The overall officials registered on this study. Names that resolve to a FindMyKOL profile link to it; the rest are shown as registered.

Daniel E Salazar, PhD
Study PI
Principal Investigator
clinicaltrials.gov ↗

A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.

Sites

35 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.

United States

Facility name not stated
Tucson, Arizona, United States
Facility name not stated
Beverly Hills, California, United States
Facility name not stated
Huntington Beach, California, United States
Facility name not stated
Redlands, California, United States
Facility name not stated
Sacramento, California, United States
Facility name not stated
Colorado Springs, Colorado, United States
Facility name not stated
Golden, Colorado, United States
Facility name not stated
New London, Connecticut, United States
Facility name not stated
Fort Myers, Florida, United States
Facility name not stated
Lakeland, Florida, United States
Facility name not stated
Melbourne, Florida, United States
Facility name not stated
Miami, Florida, United States
Facility name not stated
Palm Beach Gardens, Florida, United States
Facility name not stated
Augusta, Georgia, United States
Facility name not stated
Lemont, Illinois, United States
Facility name not stated
Oak Forest, Illinois, United States
Facility name not stated
Indianapolis, Indiana, United States
Facility name not stated
Baltimore, Maryland, United States
Facility name not stated
Glen Burnie, Maryland, United States
Facility name not stated
Boston, Massachusetts, United States
Facility name not stated
Springfield, Massachusetts, United States
Facility name not stated
Portsmouth, New Hampshire, United States
Facility name not stated
Bloomfield, New Jersey, United States
Facility name not stated
Albany, New York, United States
Facility name not stated
New York, New York, United States
Facility name not stated
Asheville, North Carolina, United States
Facility name not stated
Charlotte, North Carolina, United States
Facility name not stated
Cleveland, Ohio, United States
Facility name not stated
Youngstown, Ohio, United States
Facility name not stated
Nashville, Tennessee, United States
Facility name not stated
Abilene, Texas, United States
Facility name not stated
Austin, Texas, United States
Facility name not stated
Houston, Texas, United States
Facility name not stated
The Woodlands, Texas, United States
Facility name not stated
Richmond, Virginia, United States

Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.

Drugs studied

The drug and biological interventions registered on this study, normalized to their RxNorm ingredient where possible.

Anti-VEGFPlaceboX-82

Linked drugs open the directory filtered to KOLs working with them.clinicaltrials.gov ↗

Registration & key dates

Registry attributes as recorded on the ClinicalTrials.gov study record.

Start: 16 Mar 2015
Primary completion: 12 Dec 2017
Completion: 12 Jan 2018
Last update posted: 11 Feb 2022
Registered enrollment: 157
Registry id: NCT02348359

clinicaltrials.gov ↗

Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 4 Nov 2026. Registry facts are shown as registered by the study sponsor; FindMyKOL does not interpret them.